Medication info
Pregabalin Capsule 150 mg (Pregabalin)

Pregabalin Capsule 150 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›150mg / 1 capsule
Manufacturer / importer
Joah Pharmaceutical Co., Ltd.
Appearance
A hard capsule of white powder, with the upper and lower parts being white.
Packaging
30 capsules/bottle, 100 capsules/bottle
Approval status
Active

MFDS item code 201706343 · Approved 2017.07.31 · Insurance code 644603740

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
Who takes it
Adults · Children
Adult dose
Administer the total daily dose of pregabalin orally in 2 divided doses, with or without food. This medicine is eliminated primarily by the kidneys; therefore, the dose should be adjusted in patients with impaired renal function. (See section “5. Patients with Renal Impairment”) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The starting dose is 150 mg per day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, the dose may then be increased at 7-day intervals up to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: The starting dose is 150 mg per day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional week, it may be increased to the target dose of 600 mg per day. If the target daily dose is not tolerated, dose reduction may be considered. (See section “4. Discontinuation of Treatment”) 2. Epilepsy Adults: The starting dose is 150 mg per day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, the dose may then be increased at 7-day intervals up to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose for fibromyalgia is 300 mg to 450 mg per day. The starting dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment This medicine is eliminated primarily by the kidneys as unchanged drug after entering the systemic circulation. Because its clearance is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. In patients receiving hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined by renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. ≥60 mL/min: Starting dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30 -<60 mL/min: Starting dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15 -<30 mL/min: Starting dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15 mL/min: Starting dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: 25 mg, maximum dose 100 mg, single dose TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as indicated by the dosing regimen. b: The supplemental dose refers to an additional dose given as a single dose. 6. Patients with Hepatic Impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Older Adults (65 years of age or older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
Use is not recommended in children under 12 years of age or adolescents aged 12 to 17 years because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Joah Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to treat peripheral and central neuropathic pain in adults. Additionally, it is effective as an adjunctive therapy for patients with epilepsy, whether they experience secondary generalization of seizures or not. Moreover, it helps alleviate symptoms in patients suffering from fibromyalgia. In this way, this medication is used for various neurological disorders, contributing to improving the quality of life for patients.

How to take

Adult dose

Administer the total daily dose of pregabalin orally in 2 divided doses, with or without food. This medicine is eliminated primarily by the kidneys; therefore, the dose should be adjusted in patients with impaired renal function. (See section “5. Patients with Renal Impairment”) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The starting dose is 150 mg per day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, the dose may then be increased at 7-day intervals up to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: The starting dose is 150 mg per day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional week, it may be increased to the target dose of 600 mg per day. If the target daily dose is not tolerated, dose reduction may be considered. (See section “4. Discontinuation of Treatment”) 2. Epilepsy Adults: The starting dose is 150 mg per day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, the dose may then be increased at 7-day intervals up to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose for fibromyalgia is 300 mg to 450 mg per day. The starting dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment This medicine is eliminated primarily by the kidneys as unchanged drug after entering the systemic circulation. Because its clearance is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. In patients receiving hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined by renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. ≥60 mL/min: Starting dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30 -<60 mL/min: Starting dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15 -<30 mL/min: Starting dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15 mL/min: Starting dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: 25 mg, maximum dose 100 mg, single dose TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as indicated by the dosing regimen. b: The supplemental dose refers to an additional dose given as a single dose. 6. Patients with Hepatic Impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Older Adults (65 years of age or older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

Use is not recommended in children under 12 years of age or adolescents aged 12 to 17 years because there are insufficient safety and efficacy data.

Precautions

This medication may increase the risk of suicidal thoughts or behavior, so patients should be closely monitored for changes in mood or symptoms of depression while taking it. Patients with allergies to pregabalin or this medication's components should not take this medication. Diabetic patients should be cautious because this medication may require adjustments in their blood sugar control medications due to possible weight gain after taking it. If symptoms of angioedema, such as swelling of the face or around the mouth, occur, the medication should be discontinued immediately and a doctor consulted. The elderly should be especially careful when taking this medication as dizziness or drowsiness may increase the risk of falls at the beginning of treatment. Transient blurriness or changes in vision may occur; if these symptoms persist, consult a doctor. Care should be taken when switching from other anticonvulsants to monotherapy. Abrupt discontinuation may result in withdrawal symptoms such as insomnia, headache, nausea, anxiety, depression, and suicidal thoughts, so the dose should be gradually reduced as per a doctor's instructions. Due to the risk of substance abuse, special caution is necessary in patients with a history of mental illness or substance abuse. Patients with reduced kidney function may need dose adjustments. Patients with severe heart disease should use this medication cautiously due to possible heart failure risks. When taken with other central nervous system depressants or opioids, there may be an increased risk of respiratory depression. Women of childbearing age should use effective contraception due to the risk of fetal malformations in early pregnancy, and the medication should generally be avoided during pregnancy. During breastfeeding, this medication may pass into breast milk and affect infants, so the decision to breastfeed or take the medication should be made carefully. Activities like driving or operating machinery should be avoided until dizziness or drowsiness resolves after taking this medication. Severe skin reactions may rarely occur; if skin rashes or fever occur, discontinue the medication immediately and consult a healthcare professional. In case of overdose, symptoms such as confusion, drowsiness, depression, or seizures may appear, so immediate medical attention should be sought.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial edema
  • periorbital edema
  • upper airway edema
  • dizziness
  • drowsiness
Show 177 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • feelings of depression
  • suicidal thoughts
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • respiratory depression
  • rhinitis
  • neutropenia
  • increased appetite
  • anorexia
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • feelings of euphoria
  • decreased libido
  • depersonalization
  • sexual dysesthesia
  • agitation
  • mood swings
  • emotional blunting
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • uncontrollable urges
  • apathy
  • ataxia
  • abnormal motor coordination
  • balance disorders
  • amnesia
  • attention deficit
  • memory impairment
  • tremors
  • dysarthria
  • sensory abnormalities
  • sensory reduction
  • calming
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech disorders
  • tics
  • reflex reduction
  • movement disorders
  • psychomotor agitation
  • postural dizziness
  • hypersensitivity
  • burning sensation
  • activity tremors
  • syncope
  • confusion
  • movement reduction syndrome
  • olfactory abnormalities
  • loss of taste
  • writing disability
  • diplopia
  • vertigo
  • auditory hypersensitivity
  • 1st degree heart block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • vomiting
  • abdominal bloating
  • constipation
  • dry mouth
  • abdominal distension
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory loss
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweating
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle stiffness
  • rhabdomyolysis
  • urinary disorders
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • nipple discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling intoxicated
  • abnormal sensations
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • elevated blood glucose
  • decreased platelet count
  • reduced serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • congestive heart failure
  • pulmonary edema
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • state of confusion
  • agitation
  • restlessness
  • worsening of convulsions

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect from air and moisture, ideally at room temperature between 15 to 30 degrees Celsius. Proper storage helps maintain the drug's effectiveness and prevents degradation.

Appearance and packaging

Appearance

A hard capsule of white powder, with the upper and lower parts being white.

Package unit

30 capsules/bottle, 100 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.